济川药业(600566)：2025H1营收利润承压 流感用药获批丰富管线布局

Group 1 - The company reported a revenue of 2.749 billion yuan for H1 2025, a year-on-year decrease of 31.87%, and a net profit attributable to shareholders of 724 million yuan, down 45.87% [1] - For Q2 2025, the company achieved a revenue of 1.223 billion yuan, a decline of 25.03%, with a net profit of 284 million yuan, down 42.39% [1] - The gross margin for H1 2025 was 75.68%, a decrease of 3.89 percentage points, while the net profit margin was 26.39%, down 6.86 percentage points [1] Group 2 - The company has established a specialized academic promotion department, enhancing its market advantage and enabling rapid product market entry [2] - The approval of the product Marcilosavir tablets, developed in collaboration with Zhengxiang Pharmaceutical, enriches the company's flu medication portfolio [2] - The new drug is a first-class new drug with broad-spectrum antiviral properties against influenza viruses, targeting healthy adults with uncomplicated influenza [2]